RT Journal Article
SR Electronic
T1 Distinct serum anti-Aβ antibody patterns in hemorrhagic and inflammatory cerebral amyloid angiopathy manifestations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.07.20208330
DO 10.1101/2020.10.07.20208330
A1 Chantran, Yannick
A1 Capron, Jean
A1 Doukhi, Diana
A1 Felix, Johanna
A1 Féroul, Mélanie
A1 Kruse, Florian
A1 Chaigneau, Thomas
A1 Dorothée, Guillaume
A1 Allou, Thibault
A1 Ayrignac, Xavier
A1 Barrou, Zina
A1 de Broucker, Thomas
A1 Cret, Corina
A1 Turc, Guillaume
A1 Peres, Roxane
A1 Wacongne, Anne
A1 Sarazin, Marie
A1 Renard, Dimitri
A1 Cordonnier, Charlotte
A1 Alamowitch, Sonia
A1 Aucouturier, Pierre
YR 2020
UL http://medrxiv.org/content/early/2020/10/09/2020.10.07.20208330.abstract
AB Objective To study blood anti-Aβ antibodies in the context of spontaneous inflammatory or hemorrhagic CAA manifestations, which are similar to complications occurring after monoclonal anti-Aβ antibody immunotherapies.Methods In this case-control study, serum anti-Aβ antibody isotype, concentration, avidity, and reactivity toward soluble or fibrillary Aβ1-40 and Aβ1-42 isoforms were assessed using an ELISA-based multiplex analysis. Anti-Aβ serologic patterns were defined in CAA and CAA subgroups using multivariable logistic regression analyses.Results Fourty-one healthy aged controls and 64 CAA patients were recruited: 46 with hemorrhagic features (CAA-he) and 18 with CAA-related inflammation (CAA-ri). As compared to controls, the most striking features of CAA-related serological profiles were the following: i) both CAA-he and CAA-ri patients displayed lower binding diversity of anti-soluble Aβ1-40 IgM; ii) CAA-he patients displayed higher anti-soluble Aβ1-40 / fibrillary Aβ1-42 IgG4 concentrations ratio and higher anti-soluble Aβ1-42 IgG4 and IgA avidity; iii) CAA-ri patients displayed higher binding diversity of anti-soluble Aβ1-40 IgG3 and higher anti-fibrillary/soluble Aβ1-42 IgG4 dilution curve steepness ratio.Conclusion This proof-of-concept study revealed anti-Aβ antibody variations in CAA patients, some of which were associated to CAA clinical phenotypes, unveiling pathophysiological insights regarding CAA-hemorrhagic and inflammatory related events.Competing Interest StatementThe authors have declared no competing interest.Funding StatementStudy funding supported by the SATT LutechAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the ethics committee Paris Ile de France V.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request.